Gray, R. G., Rea, D. W., Handley, K., Marshall, A. (Andrea), Pritchard, M. G., Perry, P., Earl, H. M., Poole, Christopher, Salman, A. and Lee, M. (2008) aTTom (adjuvant Tamoxifen--To offer more?) : randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. In: 2008 ASCO Annual Meeting, Chicago, Illinois, 30 May-3 Jun 2008. Published in: Journal of Clinical Oncology, Vol.26 (No.15S (May 20 Supplement)). p. 513.

Full text not available from this repository.

Abstract

Background: In ER+ early breast cancer, 5 years of tamoxifen substantially reduces the annual recurrence rate throughout the first decade (years 0-9). Despite this, appreciable risks of recurrence remain, with similar annual recurrence risks for ER+ disease during years 0-4, 5-9 and 10-14 following surgery. It is not reliably known how 10 years duration of adjuvant tamoxifen compares with the current standard of 5 years. Methods: Between 1991 and 2005, 6,934 women with ER+ (39%), or ER untested (61%) invasive breast cancer (53% node negative, 31% node positive, 16% node status unspecified) from 176 UK centers, who had completed 4+ years of adjuvant tamoxifen, were randomized between continuing for another 5 years and stopping. Information on compliance, hospital admission(s), breast cancer recurrence (including new contralateral disease), other new primary cancer, death and cause of death was sought annually. Results: 78% of those allocated to continue and 3% of those allocated to stop were taking adjuvant tamoxifen at 3 years following randomization; fewer than 1% switched to any other adjuvant hormone treatment. With a median follow-up of 4.2 years, there were fewer recurrences (415 vs 442; RR=0.94, 95% CI 0.81-1.09; p=0.4) among those allocated to 10yrs than 5yrs tamoxifen. Although breast cancer mortality was lower among those allocated 10yrs, with just 374 deaths from breast cancer recorded, data remain immature. Despite a doubling in the risk of endometrial cancer (76 vs 35) with 10yrs tamoxifen, there was no increase in deaths from endometrial cancer (10 vs 12) or from any other non-breast cancer cause. Conclusions: Although no significant reduction in recurrence has yet been seen in aTTom, the results are consistent with preliminary findings from the ATLAS trial, which reported a DFS but not overall survival advantage to longer tamoxifen (Peto et al SABCS 2007). Combining results from these two large studies indicate that continuation of tamoxifen beyond the first 5 years reduces recurrence over the next few years, but further follow-up is needed to assess reliably the longer-term effects on recurrence and the net effects, if any, on mortality.

Item Type:	Conference Item (Paper)
Subjects:	R Medicine > R Medicine (General)
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Journal or Publication Title:	Journal of Clinical Oncology
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Date:	May 2008
Volume:	Vol.26
Number:	No.15S (May 20 Supplement)
Page Range:	p. 513
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Conference Paper Type:	Paper
Title of Event:	2008 ASCO Annual Meeting
Type of Event:	Conference
Location of Event:	Chicago, Illinois
Date(s) of Event:	30 May-3 Jun 2008
URI:	http://wrap.warwick.ac.uk/id/eprint/45231

Request changes to a record

Actions (login required)

View Item